Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.
A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.
The proposal allows pharmacies to dispense a first-time 30-day supply of the HIV prevention pill without a script.
Truvada and Descovy are both highly effective and generally safe options for HIV prevention.
This will provide free PrEP to as many as 200,000 uninsured Americans until 2030.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
Descovy and Truvada were both highly effective and generally safe options for HIV prevention in a recent clinical trial.
Pharma sets the prices for HIV and hep C drugs very high. What happens to those prices along the supply chain?
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
Researchers conducted a systematic review of antiretroviral treatment outcomes since 1994 among 78,000 people with HIV.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.